• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Issues that matter
    • COVID-19 in India
    • Inadequate safe drinking water
    • Poor sanitation
    • Environmental health
    • Infectious disease
      • Hepatitis C
    • Noncommunicable Diseases (NCDs)
    • Malnutrition
    • High infant mortality
    • Mental health
    • Sex and gender discrimination
  • Special Focus
    • Interviews
      • Exclusive Interviews
      • Readers Interviews
    • Vaccine Hesitancy
  • News
  • PandemiCast
  • Partner’s Press Office

Health Issues India

Health issues in India

  • Home
  • About Us
  • Editorial Team
  • Subscribe
  • Contribute
  • Sponsor
  • Contact Us
You are here: Home / Featured / Approval of Alzheimer’s drug “rife with irregularities”

Approval of Alzheimer’s drug “rife with irregularities”

January 4, 2023 By Lalita Panicker Leave a Comment

brain disease dementia Copyright: vampy1 / 123RF Stock PhotoUS drug regulators failed to follow their own guidance and practices when they approved the controversial Alzheimer’s drug Aduhelm, a congressional report said on Thursday. www.theguardian.com/us-news/2022/dec/29/biogen-fda-alzheimers-aduhelm-congressional-report?

The US food and drug administration’s (FDA) process of approval, it said, had been “rife with irregularities”, and the FDA’s interactions with maker Biogen had been “atypical”.

The report follows an 18-month regulatory review conducted by two House committees focused on the drug’s approval, pricing and marketing.

Biogen, the report found, had set an “unjustifiably high” price by initially pricing Aduhelm at $56,000 a year. The pricing was established despite a lack of demonstrated clinical benefit in a broad patient population.

The report said that the company’s own projections showed that it expected Aduhelm to be a burden to the government’s health insurer Medicare and costly to patients. After Biogen halved the cost, the federal insurer continued its coverage of the drug.

“The findings in this report raise serious concerns about FDA’s lapses in protocol and Biogen’s disregard of efficacy and access in the approval process for Aduhelm,” the report concluded.

FDA regulators approved Aduhelm in June 2021 under an accelerated process. The certification came over objections raised by a panel of outside advisers that had expressed doubts about its benefit to people suffering from Alzheimer’s-related dementia.

Aduhelm’s authorization was based on evidence that it could reduce brain plaques – or clumps of folded amyloid proteins, considered a probable contributor to Alzheimer’s – but not on proof that it slowed the progression of the disease.

The report found that Biogen had wanted to introduce a “blockbuster” to “establish Aduhelm as one of the top pharmaceutical launches of all time” and was prepared to commit several billion dollars – or more than two-and-a-half times what it had spent to develop the drug – promoting it to doctors, patients, advocacy groups, insurers and policymakers.

Filed Under: Featured, Featured Stories, Medicine and Research, News, Newsletter, Noncommunicable diseases Tagged With: Alzheimer's disease, FDA

Reader Interactions

Leave a Reply Cancel reply

You must be logged in to post a comment.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Articles

  • Renewed fears of a bird flu pandemic; The latest health stories from around the world
  • More oversight needed for “gain of function” research says expert panel; The latest health stories from around the world
  • Marion Biotech to be investigated by Indian drug regulator
  • Sesame to be added to list of major food allergens
  • Approval of Alzheimer’s drug “rife with irregularities”

Footer

Archives

Issues that matter

  • Environmental health
  • Inadequate safe drinking water
  • Poor sanitation
  • Infectious disease
  • Noncommunicable Diseases (NCDs)
  • Malnutrition
  • High infant mortality

Categories

Copyright © 2023 · News Pro On Genesis Framework · WordPress · Log in

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.
Cookie settingsACCEPTACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.